Although disease progression is primarily caused by the deficient dystrophin protein, combined therapy for improving the phenotype of muscle cells and preventing chronic inflammation with subsequent fibrosis may be an applicable therapeutic approach for the management of DMD [6]. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.